Revocation of authorisation for sickle cell disease medicine Adakveo

View source ↗

Summary

The European Medicines Agency revoked the authorisation for Adakveo (crizanlizumab) for the treatment of sickle cell disease in the EU.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• ADAKVEO (crizanlizumab)